Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05249803Completed

"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19

Role: lead

NCT04739410Phase 4Completed

Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients

Role: lead

NCT04730323Phase 4Completed

TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience

Role: lead

NCT04670328Completed

Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Role: lead

All 4 trials loaded